Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)

INTRODUCTION: PF-06438179, a potential biosimilar to Remicade(®) (infliximab, Janssen Biotech, Inc.), is a chimeric mouse–human monoclonal antibody targeting human tumor necrosis factor alpha (TNF). METHODS: Analytical (small subset reported here) and nonclinical studies compared the structural, fun...

Descripción completa

Detalles Bibliográficos
Autores principales: Derzi, Mazin, Johnson, Theodore R., Shoieb, Ahmed M., Conlon, Hugh D., Sharpe, Penny, Saati, Andrew, Koob, Sarah, Bolt, Michael W., Lorello, Leslie G., McNally, Jim, Kirchhoff, Carol F., Smolarek, Teresa A., Leach, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083783/
https://www.ncbi.nlm.nih.gov/pubmed/27585978
http://dx.doi.org/10.1007/s12325-016-0403-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083783/
https://www.ncbi.nlm.nih.gov/pubmed/27585978
http://dx.doi.org/10.1007/s12325-016-0403-9

Ejemplares similares